New drug cocktail targets Hard-to-Treat lung cancer
NCT ID NCT07377916
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, SHR-A1811 and pertuzumab, in people with advanced non-small cell lung cancer that has HER2 mutations or overexpression and has worsened after at least one prior treatment. The goal is to see if this combo can shrink tumors or slow disease progression. About 60 participants will receive the treatment intravenously every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811 (a drug) combined with pertuzumab
- What this could lead to
- If successful, this combination could offer a new treatment option to control advanced HER2-altered lung cancer after initial therapy fails.
- What could go wrong
- This is an early exploratory study with only 60 participants and no control group. The treatment may not improve outcomes and could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?